William Blair Weighs in on Genmab A/S FY2029 Earnings

Genmab A/S (NASDAQ:GMAB) – Stock analysts at William Blair issued their FY2029 EPS estimates for shares of Genmab A/S in a report issued on Monday, March 10th. William Blair analyst M. Phipps expects that the company will post earnings of $4.38 per share for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Several other research analysts also recently commented on the stock. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday, February 13th. Truist Financial decreased their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Stock Down 1.2 %

Shares of NASDAQ GMAB opened at $19.96 on Thursday. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.26. The firm’s fifty day moving average is $21.26 and its 200 day moving average is $22.50. The company has a market cap of $13.21 billion, a price-to-earnings ratio of 11.47, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. grew its position in shares of Genmab A/S by 16.2% in the 3rd quarter. Assetmark Inc. now owns 82,629 shares of the company’s stock worth $2,014,000 after buying an additional 11,519 shares during the period. Atria Investments Inc grew its position in shares of Genmab A/S by 42.4% in the 3rd quarter. Atria Investments Inc now owns 48,475 shares of the company’s stock worth $1,182,000 after buying an additional 14,424 shares during the period. Oppenheimer Asset Management Inc. grew its position in shares of Genmab A/S by 6.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock worth $5,662,000 after buying an additional 14,165 shares during the period. Natixis Advisors LLC grew its position in shares of Genmab A/S by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after buying an additional 47,437 shares during the period. Finally, Grandfield & Dodd LLC grew its position in shares of Genmab A/S by 25.7% in the 3rd quarter. Grandfield & Dodd LLC now owns 32,363 shares of the company’s stock worth $789,000 after buying an additional 6,610 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.